Janssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV…

Press/Media: Press / Media

PeriodApr 23 2015

Media coverage

1

Media coverage

  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV…
    Media name/outletGnom.es
    CountrySpain
    Date4/23/15
    PersonsEric J Lawitz